(Q43223330)

16 November 2017

Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge (English)

1 reference

16 November 2017

1 reference

9

1 reference

16 November 2017

6

Laia Solano-Gallego

1 reference

16 November 2017

Alhelí Rodríguez-Cortés

1

1 reference

16 November 2017

Ana Ojeda

2

1 reference

16 November 2017

Laura López-Fuertes

3

1 reference

16 November 2017

Marcos Timón

4

1 reference

16 November 2017

Laura Altet

5

1 reference

16 November 2017

Elisenda Sánchez-Robert

7

1 reference

16 November 2017

Olga Francino

8

1 reference

16 November 2017

language of work or name

English

0 references

publication date

30 August 2007

1 reference

16 November 2017

1 reference

16 November 2017

25

1 reference

16 November 2017

46

1 reference

16 November 2017

7962-7971

1 reference

Leishmaniasis: current situation and new perspectives

16 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Leishmania/HIV co-infections: epidemiology in Europe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

New perspectives on a subclinical form of visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

DNA vaccines: immunology, application, and optimization*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Nucleic acid immunization protects dogs against challenge with virulent canine parvovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Immunization of dogs and cats with a DNA vaccine against rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

DNA vaccine encoding nucleocapsid and surface proteins of wild type canine distemper virus protects its natural host against distemper

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Molecular determinants of Leishmania virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Genetic vaccination against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Immune response against Leishmania antigens in dogs naturally and experimentally infected with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Western blot analysis of Leishmania infantum antigens using sera from pentamidine-treated dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generati

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Second-generation vaccines against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Leishmaniasis: current status of vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Canine major histocompatibility complex genes DQA and DQB in Irish setter dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

A long term experimental study of canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Dynamics of Leishmania-specific immunoglobulin isotypes in dogs with clinical leishmaniasis before and after treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Plasmid DNA encoding influenza virus haemagglutinin induces Th1 cells and protection against respiratory infection despite its limited ability to generate antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Induction of protective immunity to Theileria annulata using two major merozoite surface antigens presented by different delivery systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Immunization of animals: from DNA to the dinner plate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Mapping and sequencing of the canine NRAMP1 gene and identification of mutations in leishmaniasis-susceptible dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Detailed analysis of an experimental challenge model for Leishmania infantum (JPC strain) in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

The effect of repeated leishmanin skin testing on the immune responses to Leishmania antigen in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

DNA vaccines: progress and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Human clinical trials of plasmid DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Immunization with DNA through the skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Gene-based vaccines: recent technical and clinical advances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Tissue cytokine responses in canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Canine leishmaniasis: epidemiological risk and the experimental model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

The prime-boost strategy: exciting prospects for improved vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

CD4(+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10.D2 mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

The kinetoplastid membrane protein 11 of Leishmania donovani and African trypanosomes is a potent stimulator of T-lymphocyte proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.023

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2007.08.023

1 reference

16 November 2017

1 reference